Volume : 08, Issue : 09, September – 2021
Title:
23.DEVELOPMENT AND CHARACTERIZATION OF GLICLAZIDE TRANSDERMAL PATCHES
Authors :
Nagarjuna Narala*, Srikanth Baisa
Abstract :
Gliclazide is used in the treatment of type-II diabetes. The main aim and objective is the development and characterization of GLICLAZIDE patch using various polymers such as HPMC k15m, Eudragit S100 by solvent evaporation method. Here Di-butyl phthalate is used as plasticizer and Dimethyl sulfoxide (DMSO) is used as permeation enhancer where as water and ethanol are used as solvents. The formulated patches are evaluated for thickness, weight variation, folding endurance, moisture absorption, and moisture loss along with In-vitro drug dissolution parameters. The drug release studies are carried out by Franze diffusion cell by using pH buffer solution. The drug release is carried out for 8 hrs. Before formulating, the pre formulation studies are evaluated such as FTIR, organoleptic characters such as colour, odour, and appearance. The kinetic profile data is also recorded for optimised formulation and they follow zero order reaction. The stability studies are performed for 90days for optimised formulation under accelerated conditions.
Keywords: Gliclazide, transdermal patch, 7.4 pH buffer.
Cite This Article:
Please cite this article in press Nagarjuna Narala et al, Development And Characterization Of Gliclazide Transdermal Patches., Indo Am. J. P. Sci, 2021; 08(9).
Number of Downloads : 10
References:
1. DineshNyavanandi,VenkataRamanKallakuntaSandeepSarabuArunButreddySagarNaralaaSureshBandariaMichael A.RepkaImpact of hydrophilic binders on stability of lipid-based sustained release matrices of quetiapine fumarate by the continuous twin screw melt granulation technique; Advanced Powder Technology Volume 32, Issue 7, July 2021, Pages 2591-2604.
2. Basanth Babu Eedara Dinesh Nyavanandi Sagar Narala Prabhakar Reddy Veerareddy Suresh Bandari, Improved Dissolution Rate and Intestinal Absorption of Fexofenadine Hydrochloride by the Preparation of Solid Dispersions: In Vitro and In Situ Evaluation Pharmaceutics 2021, 13(3), 310.
3. 3.Anh Q.VoGerdKutzHermanHeSagarNaralSureshBandariMichael A.RepkaContinuous Manufacturing of Ketoprofen Delayed Release Pellets Using Melt Extrusion Technology: Application of QbD Design Space, Inline Near Infrared, and Inline Pellet Size AnalysisJournal of Pharmaceutical Sciences Volume 109, Issue 12, December 2020, Pages 3598-3607.
4. Sagar Narala Dinesh Nyavanandi Priyanka Srinivasan Preethi Mandati Suresh Bandari Michael A.Repka Pharmaceutical Co-crystals, Salts, and Co-amorphous Systems: A novel opportunity of hot-melt extrusion Journal of Drug Delivery Science and Technology Volume 61, February 2021, 102209.
5. Butreddy, Arun; Nyavanandi, Dinesh; Narala, Sagar; Austin, Fischer; Bandari, Suresh Application of Hot Melt Extrusion Technology in the Development of Abuse-Deterrent Formulations: An Overview Current Drug Delivery, Volume 18, Number 1, 2021, pp. 4-18(15)
6. N. Siva Ganesh,1 M. Ratanlal , A. Venkat Narsaiah , K. V. L. D. Spandana, Sridhar Thota , Sagar Narala Development and Validation RP-HPLC Method for Estimation of Cinacalcet in Bulk and Tablet Dosage FormAm. J. PharmTech Res. 2015; 5(1)
7. Aruna Adepu , Sagar Narala , Ashok Ganji and Sapnil Chilvalvar A Review on Natural Plant: Aerva lanataInt J Pharma Sci. 2013, 3(6): 398-402
8. Sagar narala1, venkateshwar rao jupally and bhujanga rao a.k.s. Synthesis and characterization of n-substituted-5-methyl-1-(4- methylphenyl)-1h-1, 2, 3-triazole-4-carboxamide derivatives Asian J Pharm Clin Res, Vol 5, Issue 1, 2012, 89-94.
9. Ahad A., Aqil M., A review on transdermal drug delivery: the essential challenges and technological developments, Transdermal drug transformation /Asian Journal of Pharmaceutical Sciences 2010, 5 (6): 276-288.
10. Shingade GM, Aamer Quazi, , Jadhav SL, Gaikwad DD, Review on: Transdermal drug delivery advantages the current study 2012, 2(1).
11. Sharma Nikhi, Parashar Bharat, Sharma Shalini, flourishing pharma industry with transdermal drug delivery system advantages and advancements for future prospects. 2012; 2(3), 262- 278.
12. Premjeet Sandhu, Bilandi Ajay, The profits of transdermal drug transfusion from skin membrane to blood stream. IJRPC 2011, 1(4).
13. Patel Harunusman, Patel Upendra Daslaniya, , The review on Transdermal drug delivery system as prominent, Dosage forms and their limitations in this review. 2012, 1(3), 42-65.
14. L Latheeshjlal., Phanitejaswini P.A review on transdermal drug delivery system need for the study , 3(4), pp 2140-2148.
15. Fukushima, Keizo, et al. The transdermal drug delivery formulation factors such as physiological factors. 28.1 (2011): 7-15.
16. Science Fact Finder The review on transdermal formulation factors 2006 -1-Jan. (accessed 2014 26-Jan).
17. Jasti BR, Abraham W, Ghosh TK A review on Transdermal drug delivery mechanism of action of Transdermal and Topical drug delivery systems. 2005. p. 423-53.
18. Franz TJ, Tojo K. Shah KR, A review on Transdermal patch delivery mechanism such as “ELECTROPORATION”, 1992:341-421.
19. Prochazka AV, the novel development o trans dermal drug delivery mechanism by applying the ultrasound.2000; 117 (4):169-175.